Literature DB >> 30066313

Reply to Ward and Colleagues' Comment on "Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors".

Rebecca N Jerome1, Jill M Pulley2, Dan M Roden3, Jana K Shirey-Rice2, Lisa A Bastarache4, Gordon Bernard2,3, Leeland Ekstrom2,5, William J Lancaster4, Joshua C Denny4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30066313     DOI： 10.1007/s40264-018-0701-z

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  2 in total

1.  Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.

Authors:  Dong An; Xiaowei Wei; Hui Li; Hui Gu; Tianchu Huang; Guifeng Zhao; Bo Liu; Weilin Wang; Lizhu Chen; Wei Ma; Henan Zhang; Songying Cao; Zhengwei Yuan
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

2.  Comment on "Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors".

Authors:  Lucas D Ward; Graeme J Moffat; Jing Yuan; Paul Nioi
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.